{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:33Z","timestamp":1792806153367,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113431","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:59:27Z","timestamp":1783954767000},"page":"113431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"239","author":[{"given":"Bernardo F.","family":"Spiazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina P.","family":"Zingano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica","family":"Colpani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gerchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diabres.2026.113431_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25\u00a0years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113431_b0010","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. Jul 15 2023;402(10397):203-234. doi:10.1016\/s0140-6736(23)01301-6.","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"10.1016\/j.diabres.2026.113431_b0015","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 11th edn. 2025. https:\/\/www.diabetesatlas.org."},{"issue":"16","key":"10.1016\/j.diabres.2026.113431_b0020","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/archinte.167.16.1720","article-title":"Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons","volume":"167","author":"Bogers","year":"2007","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113431_b0025","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.CIR.67.5.968","article-title":"Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study","volume":"67","author":"Hubert","year":"1983","journal-title":"Circulation"},{"issue":"9921","key":"10.1016\/j.diabres.2026.113431_b0030","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0140-6736(13)61836-X","article-title":"Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1\u00b78\u00a0million participants","volume":"383","author":"Lu","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2026.113431_b0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.108.772962","article-title":"Prediction of first events of coronary heart disease and stroke with consideration of adiposity","volume":"118","author":"Wilson","year":"2008","journal-title":"Circulation"},{"issue":"9733","key":"10.1016\/j.diabres.2026.113431_b0040","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2026.113431_b0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79\u00a0million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"10.1016\/j.diabres.2026.113431_b0050","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"issue":"10138","key":"10.1016\/j.diabres.2026.113431_b0055","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(18)30314-3","article-title":"Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data","volume":"391","author":"Gregg","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.diabres.2026.113431_b0060","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113431_b0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113431_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.diabres.2026.113431_b0075","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2026.113431_b0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.diabres.2026.113431_b0085","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10295","key":"10.1016\/j.diabres.2026.113431_b0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2026.113431_b0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10300","key":"10.1016\/j.diabres.2026.113431_b0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.diabres.2026.113431_b0105","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2026.113431_b0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with Type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.diabres.2026.113431_b0115","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.diabres.2026.113431_b0120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.diabres.2026.113431_b0125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113431_b0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.diabres.2026.113431_b0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2026.113431_b0140","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2026.113431_b0145","doi-asserted-by":"crossref","unstructured":"Kadowaki T, Kiyosue A, Shingaki T, Oura T, Yokote K. Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Diabetes Endocrinol. Feb 27 2025;doi:10.1016\/s2213-8587(24)00377-2.","DOI":"10.1016\/S2213-8587(24)00377-2"},{"issue":"3","key":"10.1016\/j.diabres.2026.113431_b0150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.diabres.2026.113431_b0155","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113431_b0160","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113431_b0165","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113431_b0170","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane; 2024. www.training.cochrane.org\/handbook."},{"issue":"1","key":"10.1016\/j.diabres.2026.113431_b0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"issue":"7414","key":"10.1016\/j.diabres.2026.113431_b0180","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.diabres.2026.113431_b0185","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"10.1016\/j.diabres.2026.113431_b0190","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113431_b0195","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2026.113431_b0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.diabres.2026.113431_b0205","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.diabres.2026.113431_b0210","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113431_b0215","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"10160","key":"10.1016\/j.diabres.2026.113431_b0220","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2026.113431_b0225","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.diabres.2026.113431_b0230","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1007\/s12325-023-02536-8","article-title":"A phase 1 multiple dose study of tirzepatide in chinese patients with type 2 diabetes","volume":"40","author":"Feng","year":"2023","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.diabres.2026.113431_b0235","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2026.113431_b0240","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2213-8587(25)00248-7","article-title":"Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Guo","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113431_b0245","unstructured":"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes. National Library of Medicine (US). https:\/\/clinicaltrials.gov\/study\/NCT05963022."},{"issue":"5","key":"10.1016\/j.diabres.2026.113431_b0250","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/ANNALS-24-03849","article-title":"Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide: a randomized clinical trial","volume":"178","author":"Billings","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2026.113431_b0255","unstructured":"Guidance for Industry Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) 2008. http:\/\/web.archive.org\/web\/20170120130954\/http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf."},{"key":"10.1016\/j.diabres.2026.113431_b0260","doi-asserted-by":"crossref","DOI":"10.2337\/dc26-0298","article-title":"Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND","author":"Sattar","year":"2026","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2026.113431_b0265","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:12:44Z","timestamp":1792804364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"alternative-id":["S0168822726003517"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113431","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113431"}}